Trial Profile
Phase II Trial of low-dose Sandimmun Optoral (Cyclosporine A) for the treatment of primary Sjogren's syndrome (pSS)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Jun 2022
Price :
$35
*
At a glance
- Drugs Ciclosporin (Primary)
- Indications Sjogren's syndrome
- Focus Therapeutic Use
- Acronyms CYPRESS
- 28 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 25 Sep 2012 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health; NCT01693393).
- 25 Sep 2012 Planned end date 1 Mar 2014 added as reported by ClinicalTrials.gov.